Incyte posts results for Phase 1/2 anti-PD-1, LAG-3, TIM-3 combo trial in advanced malignancies
Incyte's trial testing INCMGA00012, INCAGN02385, and INCAGN02390 together in select advanced malignancies has completed, with results posted to the registry.
Incyte's registry activity this week centers on a completed combination immunotherapy trial with results now posted.
- This is a Phase 1/2 study of the triplet combination of INCMGA00012 (anti-PD-1), INCAGN02385 (anti-LAG-3), and INCAGN02390 (anti-TIM-3) in participants with select advanced malignancies1, sponsored by Incyte Corporation. The trial started on 2020-07-27 and reached primary and study completion on 2025-08-251, with results first posted on 2026-08-17. Enrollment totaled 61 participants (actual)1, and the study aimed to determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA000121.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.